PLK1 and prostate neoplasm: Collectively, this study demonstrates that the oncogenic PLK1 inhibits PHGDH, and subsequently compensatory serine uptake and changes in sphingolipid metabolism ultimately drive the cellular proliferation and prostate tumor growth.